Physician profile
Xi Chen
NPI 1144515834
$9,901.30
in general payments reported to CMS, 2019-2025
15 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,768 · 2020: $26.80 · 2021: $1,135 · 2022: $1,424 · 2023: $1,309 · 2024: $983 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,505 · Food and Beverage: $1,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,505.02 |
| Food and Beverage | $1,042.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $4,550.00 | 2019 | |
| Alcon Vision LLC | $2,637.29 | 2021-2023 | Clareon |
| Spark Therapeutics, INC. | $865.00 | 2024 | Luxturna |
| Bausch & Lomb Americas INC. | $273.60 | 2022-2024 | Visudyne, Retisert, Xipere |
| Eyepoint US, INC. | $271.95 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $225.10 | 2023-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $213.37 | 2021-2022 | |
| Dutch Ophthalmic, USA | $150.00 | 2023 | Tissueblue, Eva, Combined Machine |
| Carl Zeiss Meditec, INC. | $141.73 | 2019 | |
| Ani Pharmaceuticals, INC. | $122.23 | 2025 | Iluvien |
| Ocular Therapeutix, INC. | $119.91 | 2020-2023 | Dextenza |
| Abbvie INC. | $103.34 | 2022 | |
| Innocoll Pharmaceuticals Limited | $100.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $76.00 | 2019 | |
| Genentech, INC. | $51.17 | 2023 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xi Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.